Ocular Melanoma clinical trials at UCSF

2 in progress, 0 open to eligible people

Showing trials for

  • IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

    Sorry, in progress, not accepting new patients

    This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).

    San Francisco, California and other locations

  • Neoadjuvant Darovasertib in Primary Uveal Melanoma

    Sorry, not currently recruiting here

    This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)

    San Francisco, California and other locations

Last updated: